Cancer drug set for NHS fast-track
Friday 24 December 2010
A new drug to treat advanced kidney cancer has been fast-tracked for use on the NHS, a health watchdog said yesterday.
The National Institute for Health and Clinical Excellence (Nice) is recommending Votrient (pazopanib). Pharmaceutical giant GlaxoSmithKline has agreed to a 12.5 per discount to the NHS, following the outcome of a clinical trial, comparing the drug with Sutent (sunitinib), which is already approved.
Dr Carole Longson, from Nice, said: "Pazopanib will offer patients an additional option and, for some, a more favourable side-effect profile."
Each year more than 8,000 new cases of kidney cancer are diagnosed in the UK, and almost half will lead to death.
Life & Style blogs
- 1 Cyclist who knocked down three-year-old girl says his life has been 'destroyed'
- 2 A politically correct lefty goes to see Top Gear live – you'll probably believe what happened next
- 3 Isis burns woman alive for refusing to engage in 'extreme' sex act, UN says
- 4 Puerto Rico, island of lost dreams: People are leaving the debt-hit territory in droves as near neighbour Cuba's star rises
- 5 Snoop Dogg on why he doesn't regret displaying misogyny towards women
£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...
£35 - 40k + Benefits: Guru Careers: We are seeking a Software Developer (JavaS...
£18000 - £23000 per annum + Commission: SThree: As a Trainee Recruitment Consu...